About
Lipum AB is a clinical-stage biotech company developing SOL-116, a humanized antibody targeting chronic inflammatory diseases such as rheumatoid arthritis, and has completed a Phase 1 clinical trial demonstrating safety and supporting further development.
Explore Lipum AB's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.